-
Surgical aortic valve replacement (SAVR) remains the gold standard treatment for calcific aortic stenosis (AS). However, AS is predominantly a disease of the elderly and, thus, many patients have significant comorbidities that make SAVR very high risk.
-
Little is known about the least common of left ventricular (LV) remodeling abnormalities, low ejection fraction (EF) with no cavity dilation or non-dilated cardiomyopathy.
-
The number of patients with implantable pacemakers and implantable defibrillators has increased markedly in recent years. Unfortunately, cardiac rhythm device (CRM)-related infections have also increased, and management of these infections is often problematic.
-
The Rate Control Efficacy in Permanent Atrial Fibrillation (RACE II) study compared two different strategies for rate control in patients with permanent atrial fibrillation.
-
-
Examining the three arms of the ACCORD trial; and FDA Actions: clopidogrel, dexlansoprazole, and tamsulosin.
-
The American Society of Echocardiography (ASE) has recommended that quantitative techniques be used to assess the severity of mitral regurgitation (MR) by echocardiography.
-
Although age is a risk factor for morbidity and mortality with cardiac surgery, chronologic age does not always reflect biological age. Although frailty has been shown to predict falls, hospitalization, institutionalization, and mortality in geriatric populations in the community, it has not been systematically studied in patients undergoing surgery.
-
Non-ST elevation (NSTE) acute coronary syndromes (ACS) can be managed by either an early invasive or early conservative strategy, with most data favoring an early invasive strategy in moderate- and high-risk patients.
-
Examining the three arms of the ACCORD trial; and FDA Actions: clopidogrel, dexlansoprazole, and tamsulosin.